Rohit Gosain/LinkedIn
Oct 27, 2025, 08:00
Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation
Rohit Gosain, Medical Director of Roswell Park Comprehensive Cancer Center, posted on LinkedIn:
“Revumenib is now FDA approved for R/R AML with NPM1 mutation (approved for KMT2A translocation previously).
– ORR 46.9%
– Response seen in all subgroups (comutations, previous HSCT, or high number of prior lines of Rx).”

Stay informed with Hemostasis Today.
-
Jul 9, 2026, 19:20Bradley Maron: The Beginning of a New Chapter for Circulation
-
Jul 9, 2026, 19:00Wolfgang Miesbach: ISTH 2026 Showcases the Future of Gene Therapy
-
Jul 9, 2026, 18:21Martin Vanden Eede: Can We Safely Reduce Anticoagulation During ECMO?
-
Jul 9, 2026, 18:00Dorothée Faille: Discovering Versailles During ISTH 2026
-
Jul 9, 2026, 16:45Rutbaa Ayaz Shaikh: One Step Further in Medical Research
-
Jul 9, 2026, 14:49Celebrating a Century of von Willebrand Disease Research and Care – Seminars in Thrombosis and Hemostasis
-
Jul 9, 2026, 14:38Valance Washington: International Hemostasis Community Prepares for GRC 2026
-
Jul 9, 2026, 14:27Dima Shulkin: Next-Generation AI Models Improve Early Sepsis Recognition
-
Jul 9, 2026, 14:12Omar Hajji: Seasonal Determinants of Mortality in Sepsis and Cardiogenic Shock